Good post on Yahoo .. Thx Benjamin.Potentially, yes. If we look at the case explosion in 90% vakx'd Israel, we could easily see the same ballpark results happen throughout the world this fall (an explosion in cases). Everyday, the injections keep facing more regulatory scrutiny and point-of-attack early COVID therapeutics make more sense. Revive has a real chance here along with several others. Political pressure will be to EUA a next round of safe oral therapeutic candidates. If the data is there, irrespective of U.S. adoption because of a politicized FDA, Bucillamine will be adopted in many nations.